Shanghai, 19 November 2026 – Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. has approved a plan to repurchase between RMB20 million and RMB40 million of its A shares using its own funds. The board approved the programme on 18 November, and the company’s announcement dated 19 November sets a purchase-price ceiling of RMB50 per share.
For investors in China’s listed healthcare companies, this is an authorised capital-allocation plan rather than a completed buyback. The shares are intended for employee ownership or equity incentives. Actual spending and the number of shares acquired will depend on execution, while a later employee allocation or cancellation could produce different outcomes for the share base.
Unlock the Full Article
This article is exclusive to The Ledger Asia Subsribers / PAID members.
Already have an account? Log in here